Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the ef...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	PAGEPress Publications 2025-07-01
Σειρά:	Dermatology Reports
Θέματα:	Psoriasis adalimumab biosimilars efficacy safety
Διαθέσιμο Online:	https://www.pagepress.org/journals/dr/article/view/10315
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!